Cargando…
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
The treatment of metastatic non-small cell lung cancer (NSCLC) has undergone a paradigm shift over the last decade. Better molecular characterization of the disease has led to the rapid improvement of personalized medicine and the prompt delivery of targeted therapies to patients with NSCLC. The dis...
Autores principales: | Gristina, Valerio, La Mantia, Maria, Iacono, Federica, Galvano, Antonio, Russo, Antonio, Bazan, Viviana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766858/ https://www.ncbi.nlm.nih.gov/pubmed/33352844 http://dx.doi.org/10.3390/ph13120474 |
Ejemplares similares
-
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
por: Passiglia, Francesco, et al.
Publicado: (2021) -
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021) -
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
por: Gristina, Valerio, et al.
Publicado: (2022) -
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
por: Incorvaia, Lorena, et al.
Publicado: (2019) -
A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic
por: Pisapia, Pasquale, et al.
Publicado: (2021)